{"entity":{"id":"curis","kind":"company","name":"Curis","aka":["Curis, Inc."],"tldr":"Curis is a United States-based biotechnology company running 2 late-stage cancer trials of Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma.","summary":"Curis, based in Lexington, MA, the United States, is a biotechnology company. Curis is a biotechnology company developing differentiated therapeutics for cancer patients, including an IRAK4 inhibitor in clinical development for haematologic malignancies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma. The largest, NCT03328078 (CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.curis.com"},{"label":"ClinicalTrials.gov: trials led by Curis","url":"https://clinicaltrials.gov/search?lead=Curis%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","primary-cns-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["emavusertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://www.curis.com","stage":"public","investors":[],"funding":[]},"route":"/companies/curis/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"}],"drug":[{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/"}],"trial":[{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/"},{"id":"nct03328078","kind":"trial","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","route":"/trials/nct03328078/"}]}}